Recommended Free Tools
Liverpool’s new robotic infection-research facility is called the Liverpool Accelerate Laboratory, formerly the Liverpool Robotic Infection Research Laboratory. It launched in September 2026, but that milestone does not mean it was already fully open: the Liverpool City Region Combined Authority said full opening was due in 2027.
What is the Liverpool Accelerate Laboratory?
Hosted by the Liverpool School of Tropical Medicine (LSTM) and developed through the LSTM-led iiCON partnership, the Liverpool Accelerate Laboratory is a £20 million high-containment research facility. LSTM describes it as combining artificial intelligence, robotics and human organoid technology to support infectious-disease research and the development of drugs, vaccines and diagnostics. LSTM’s opening announcement and its facility page set out its name, cost and intended work.
As an Amazon Associate I earn from qualifying purchases.
The facility includes Containment Level 3 facilities, automated liquid-handling systems, integrated robotics and AI or machine-learning tools, human organoid platforms and high-throughput screening. These capabilities are intended to help researchers carry out complex biological workflows and screen potential interventions. The published descriptions do not provide measured performance gains for this specific laboratory.
Has construction finished, and when did it open?
The September 2026 announcements describe distinct milestones. The Liverpool City Region Combined Authority said the facility launched on 4 September and was due to open fully in 2027. LSTM announced its official opening on 7 September 2026. Neither announcement establishes that routine full operations had begun by those dates. See the Combined Authority announcement and LSTM announcement.
#1 Best Overall
How could robots and organoids support infection research?
Robotics and automated liquid handling can perform repeatable steps in laboratory workflows, while high-throughput screening allows researchers to assess many potential candidates. The laboratory’s AI and machine-learning systems are described as integrated research tools; the published facility information does not quantify their effect on research speed or success.
Organoids are laboratory-grown models based on human cells. LSTM says the facility will use human organoid platforms, and the regional authority describes the intended work as developing treatments using these models. This is the facility’s stated research approach, not evidence that any particular drug, vaccine or diagnostic has already resulted from it.
Who can use the facility, and how is it funded?
The Combined Authority says the laboratory is intended to be available to academic and industry collaborators developing new treatments using human organoids. The authority reported £10 million of support from the Liverpool City Region Life Sciences Innovation Zone. It also forecast £40 million in investment over the facility’s first three years; that figure is a projection, not money reported as already generated. The facility’s stated cost is £20 million. The authority’s announcement gives the funding and forecast figures.
Why is the facility described as the UK’s first?
LSTM Pro Vice-Chancellor for Research and Innovation Professor Giancarlo Biagini described it as “the first High Containment Level 3 robotic lab in the UK.” He said it is designed to automate complex biological processes and accelerate the discovery of treatments for deadly infections. This is LSTM’s characterization of the facility; the available announcements do not provide a like-for-like comparison with other laboratories.
Quick Recap
Rank #3
Product prices and availability are accurate as of the date/time indicated and are subject to change. Any price and availability information displayed on Amazon at the time of purchase will apply.
